Filing Details
- Accession Number:
- 0001209191-23-005744
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-31 17:10:59
- Reporting Period:
- 2023-01-27
- Accepted Time:
- 2023-01-31 17:10:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1422143 | Kura Oncology Inc. | KURA | Pharmaceutical Preparations (2834) | 611547851 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1821709 | Stephen Dale | C/O Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego CA 92130 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-01-27 | 4,385 | $13.89 | 32,515 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-27 | 4,840 | $13.87 | 27,675 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
- This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022.
- This transaction was executed in multiple trades at prices ranging from $13.62 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.